Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas — TENEC

Neuroendocrine Carcinomas Clinical Trial

Official title:
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy

Status Completed

Clinical Trial Summary

To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04122911
Study type	Interventional
Source	National Cancer Institute, Naples
Contact
Status	Completed
Phase	Phase 2
Start date	January 29, 2017
Completion date	December 16, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02820857` - Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer	Phase 2
Recruiting	`NCT06041516` - Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas	Phase 1
Active, not recruiting	`NCT02695459` - Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin	Phase 2
Completed	`NCT02457273` - Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients	Phase 2
Recruiting	`NCT01203306` - Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors	Phase 2
Recruiting	`NCT05337735` - A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers	Phase 2